Foli Bio
Long Island City
About Foli Bio
Foli Bio is a precision medicine company transforming gastrointestinal disease diagnosis and drug development through Foli-seq, a novel non-invasive gut transcriptomics platform. By decoding exfoliated human RNA from stool, Foli-seq delivers deep mechanistic insight into inflammation, barrier dysfunction and treatment response. We are building a scalable insight engine that not only powers our internal diagnostic programs and partnered biomarker discovery across pharma pipelines but also serves as the foundation for AI-driven prediction, stratification, and patient monitoring. Ultimately, Foli-seq is positioned to evolve into a domain-specific foundation model for gut diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.6M
- Funding stage: Seed
- Last round: Grant (Jul 2025)
- Website: foli.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Precision Medicine
Social Profiles
Canonical: https://fsome.com/organization/foli-bio-125857 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.